top of page

KiraGen Competes at Harvard Business School's New Venture Competition

We are thrilled to announce KiraGen Bio's participation in the prestigious Harvard New Venture Competition, a testament to our dedication to pioneering advancements in CAR-T cell therapies for solid tumors. Amidst a competitive field of 78 innovative teams, KiraGen Bio showcased our groundbreaking approach to conquering the challenges of the tumor microenvironment (TME) and enhancing gene editing strategies for CAR-T cells.

The Business Track of the New Venture Competition served as an invaluable platform for integrating entrepreneurship principles into our mission. It enabled us to not only present our AI-driven platform but also engage with the complex process of transforming our research into viable, life-saving treatments.

Throughout the competition, the feedback we received was immensely beneficial, offering insights that will fuel our progress. Whether advancing to the next round or not, the experience has been enriching, reinforcing our commitment to excellence and innovation in biotechnology.

As we continue our journey at KiraGen Bio, we remain focused on merging advanced AI with deep biological understanding to revolutionize CAR-T cell therapies. Our participation in Harvard's New Venture Competition underscores our passion and dedication to making a significant impact in the fight against solid tumors.

Stay tuned for more updates on our journey and how we're transforming the landscape of cancer treatment, one innovation at a time.


bottom of page